These findings suggest that the in vivo antitumor effects of trastuzumab are accompanied by tumor-infiltrating ADCC-inducible CD11b-positive immune cells such as NK cells, macrophages and granulocyte. This evidence concerns the gene ITGAM and neoplasm.